Vascular endothelial growth factor gene therapy - Biosidus S.A.Alternative Names: VEGF GENE Therapy - Biosidus S.A.
Latest Information Update: 21 Jan 2016
At a glance
- Originator Biosidus S.A.
- Class Cytokine genes; Gene therapies; Growth factors
- Mechanism of Action Angiogenesis inducing agents; Gene transference; Vascular endothelial growth factor A stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Ischaemic heart disorders
Most Recent Events
- 21 Jan 2016 Phase-I development is ongoing in Argentina
- 17 Sep 2013 Phase-I clinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)
- 17 Sep 2013 Preclinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)